This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Neogen Q1 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.
AHCO vs. LZAGY: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. LZAGY: Which Stock Is the Better Value Option?
Is AdaptHealth (AHCO) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AdaptHealth Corp. (AHCO) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of 10.53% and 0.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
by Zacks Equity Research
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
Implied Volatility Surging for AdaptHealth (AHCO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
AHCO or PBH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. PBH: Which Stock Is the Better Value Option?
Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ
by Zacks Equity Research
KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.
AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of -66.67% and 2.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 9.03% and 5.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Philips' (PHG) first-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.
AHCO vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. BSX: Which Stock Is the Better Value Option?
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
AHCO or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. BSX: Which Stock Is the Better Value Option?
Philips (PHG) Boosts Patient Monitoring With smartQare Deal
by Zacks Equity Research
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
AHCO vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. BSX: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.
AHCO vs. HLN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AHCO vs. HLN: Which Stock Is the Better Value Option?
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AdaptHealth Corp. (AHCO) and Ascendis Pharma A/S (ASND) have performed compared to their sector so far this year.
Do Options Traders Know Something About AdaptHealth (AHCO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.
AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of 45.45% and 3.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -30.77% and 15.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Soars 19.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Are Options Traders Betting on a Big Move in AdaptHealth (AHCO) Stock?
by Zacks Equity Research
Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.